The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults
Open accessAbstract
This clinical practice guideline is a focused update on management of Clostridioides difficile infection (CDI) in adults specifically addressing the use of fidaxomicin and bezlotoxumab for the treatment of CDI. This guideline was developed by a multidisciplinary panel representing the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA). This guideline is intended for use by healthcare professionals who care for adults with CDI, including specialists in infectious diseases, gastroenterologists, hospitalists, pharmacists, and any clinicians and healthcare providers caring for these patients. The panel’s recommendations for the management CDI are based upon evidence derived from topic-specific systematic literature reviews. Summarized below are the recommendations for the management of CDI in adults. The panel followed a systematic process which included a standardized methodology for rating the certainty of the evidence and strength of recommendation using the GRADE approach (Grading of Recommendations Assessment, Development, and Evaluation). A detailed description of background, methods, evidence summary and rationale that support each recommendation, and knowledge gaps can be found online in the full text.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Clinical Practice Guidelines We Can Trust
Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Board on Health Care Services, & Institute of Medicine (2011) · National Academies Press eBooks · doi:10.17226/13058 · Cited by 3,081
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Self-citationMcDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1085 · Cited by 2,690 · cited 5×
“The previous iteration of the treatment guidelines recommended either vancomycin or fidaxomicin for treatment of an initial CDI episode for both nonsevere and severe (but not fulminant) disease [1].”
InfluentialSelf-citationFidaxomicin versus Vancomycin for Clostridium difficile Infection
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910812 · Cited by 1,585
Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant
DeFilipp, Z., Bloom, P. P., Torres Soto, M., Mansour, M. K., Sater, M. R. A., Huntley, M. H., Turbett, S., Chung, R. T., Chen, Y.-B., & Hohmann, E. L. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910437 · Cited by 1,281
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection
Wilcox, M. H., Gerding, D. N., Poxton, I. R., Kelly, C., Nathan, R., Birch, T., Cornely, O. A., Rahav, G., Bouza, E., Lee, C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1602615 · Cited by 858
Self-citationTrends in U.S. Burden of Clostridioides difficile Infection and Outcomes
Guh, A. Y., Mu, Y., Winston, L. G., Johnston, H., Olson, D., Farley, M. M., Wilson, L. E., Holzbauer, S. M., Phipps, E. C., Dumyati, G. K., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910215 · Cited by 851
Cornely, O. A., Crook, D. W., Esposito, R., Poirier, A., Somero, M. S., Weiss, K., Sears, P., & Gorbach, S. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70374-7 · Cited by 761
Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
Cornely, O. A., Miller, M. A., Louie, T. J., Crook, D. W., & Gorbach, S. L. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis462 · Cited by 401
Louie, T. J., Cannon, K., Byrne, B., Emery, J., Ward, L., Eyben, M., & Krulicki, W. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis338 · Cited by 310
Guery, B., Menichetti, F., Anttila, V.-J., Adomakoh, N., Aguado, J. M., Bisnauthsing, K., Georgopali, A., Goldenberg, S. D., Karas, A., Kazeem, G., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30751-x · Cited by 227
Gerding, D. N., Kelly, C. P., Rahav, G., Lee, C., Dubberke, E. R., Kumar, P. N., Yacyshyn, B., Kao, D., Eves, K., Ellison, M. C., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy171 · Cited by 204
Self-citationClinical and Healthcare Burden of Multiple Recurrences of Clostridium difficile Infection
Sheitoyan-Pesant, C., Chakra, C. N. A., Pépin, J., Marcil-Héguy, A., Nault, V., & Valiquette, L. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ958 · Cited by 144
Is Fidaxomicin Worth the Cost? An Economic Analysis
Bartsch, S. M., Umscheid, C. A., Fishman, N. O., & Lee, B. Y. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit346 · Cited by 108
Mikamo, H., Tateda, K., Yanagihara, K., Kusachi, S., Takesue, Y., Miki, T., Oizumi, Y., Gamo, K., Hashimoto, A., Toyoshima, J., et al. (2018) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2018.05.010 · Cited by 86
Prabhu, V. S., Dubberke, E. R., Dorr, M. B., Elbasha, E. H., Cossrow, N., Jiang, Y., & Marcella, S. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix809 · Cited by 71
Madoff, S. E., Urquiaga, M., Alonso, C. D., & Kelly, C. P. (2019) · Anaerobe · doi:10.1016/j.anaerobe.2019.102098 · Cited by 68
Self-citationCost-Effectiveness Analysis of Six Strategies to Treat Recurrent Clostridium difficile Infection
Lapointe‐Shaw, L., Tran, K. L., Coyte, P. C., Hancock, R., Powis, J. E., Poutanen, S. M., & Hota, S. S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149521 · Cited by 64
Development and Validation of a Clostridium difficile Health-related Quality-of-Life Questionnaire
Garey, K. W., Aitken, S. L., Gschwind, L., Goddu, S., Xie, Y., Duff, C., Barbut, F., Shah, D. N., & DuPont, H. L. (2016) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000473 · Cited by 57
Self-citationWatt, M., McCrea, C., Johal, S., et al. (2016) · Infection · doi:10.1007/s15010-016-0894-y · Cited by 48
Hengel, R. L., Ritter, T. E., Nathan, R. V., Anglen, L. J. V., Schroeder, C. P., Dillon, R. J., Marcella, S. W., & Garey, K. W. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa097 · Cited by 47
Self-citationOksi, J., Aalto, A., Säilä, P., Partanen, T., Anttila, V., & Mattila, E. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03630-y · Cited by 42
Soriano, M. M., Danziger, L. H., Gerding, D. N., & Johnson, S. (2014) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofu069 · Cited by 41
Self-citationCornely, O. A., Watt, M., McCrea, C., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky184 · Cited by 30
Chilton, C. H., Crowther, G. S., Todhunter, S. L., Ashwin, H. M., Longshaw, C. M., Karas, A., & Wilcox, M. H. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv156 · Cited by 28
Self-citationLam, S. W., Neuner, E. A., Fraser, T. G., Delgado, D., & Chalfin, D. B. (2018) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2018.139 · Cited by 25
Rubio‐Terres, C., Aguado, J. M., Almirante, B., Cobo, J., Grau, S., Salavert, M., Sánchez, E. G. A., Gutiérrez, C. L., & Rubio-Rodríguez, D. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03503-4 · Cited by 24
Birch, T., Golan, Y., Rizzardini, G., Jensen, E. H., Gabryelski, L. J., Güriş, D., & Dorr, M. B. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky182 · Cited by 23
Salavert, M., Cobo, J., Pascual, Á., Aragón, B., Maratia, S., Jiang, Y., Aceituno, S., & Grau, S. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0813-y · Cited by 23
Yee, K. L., Kleijn, H. J., Kerbusch, T., Matthews, R. P., Dorr, M. B., Garey, K. W., & Wrishko, R. E. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01971-18 · Cited by 23
Self-citation
Cited by
Fecal microbiota transplantation: current challenges and future landscapes
Yadegar, A., Bar-Yoseph, H., Monaghan, T. M., Pakpour, S., Severino, A., Kuijper, E. J., Smits, W. K., Terveer, E. M., Neupane, S., Nabavi-Rad, A., et al. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00060-22 · Cited by 351
Khanna, S., Assi, M., Lee, C., Yoho, D., Louie, T., Knapple, W., Aguilar, H., Garcia-Diaz, J., Wang, G. P., Berry, S. M., et al. (2022) · Drugs · doi:10.1007/s40265-022-01797-x · Cited by 301
“Clinical guidelines recommend a two-step or three-step testing algorithm to diagnose CDI [5, 6], but clinical practice relies on symptoms and available testing, most frequently PCR in the USA [14].”
Sims, M. D., Khanna, S., Feuerstadt, P., Louie, T. J., Kelly, C. R., Huang, E. S., Hohmann, E. L., Wang, E. E. L., Oneto, C., Cohen, S. H., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.55758 · Cited by 83
Self-citationTargeting the human gut microbiome with small-molecule inhibitors
Woo, A. Y. M., Aguilar Ramos, M. A., Narayan, R., Richards-Corke, K. C., Wang, M. L., Sandoval-Espinola, W. J., & Balskus, E. P. (2023) · Nature Reviews Chemistry · doi:10.1038/s41570-023-00471-4 · Cited by 42
Gut microbiota resilience and recovery after anticancer chemotherapy
Roggiani, S., Mengoli, M., Conti, G., Fabbrini, M., Brigidi, P., Barone, M., D'Amico, F., & Turroni, S. (2023) · Microbiome Research Reports · doi:10.20517/mrr.2022.23 · Cited by 31
Metadata
- Authors
- Johnson, S., Lavergne, V., Skinner, A. M., Gonzales-Luna, A. J., Garey, K. W., Kelly, C. P., & Wilcox, M. H.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-06-14
- Volume
- 73
- Issue
- 5
- Pages
- e1029-e1044
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W3175883958
- Cited by
- 674
- References
- 32
- FWCI
- 31.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.